Ryan Ashkar

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer

Laura A. Sena, Julia Fountain, Pedro Isaacsson Velho et al. · The Oncologist · 2020 · 58 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Differential Activity of PARP Inhibitors in<i>BRCA1</i>- Versus<i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer

Fadi Taza, Albert Holler, Wei Fu et al. · JCO Precision Oncology · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Jacob J. Orme, Fadi Taza, Navonil De Sarkar et al. · European Urology Oncology · 2023 · 17 citations · Full text

Medicine, Molecular Biology, Oncology +14

Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors

Ryan Ashkar, Darren R. Feldman, Nabil Adra et al. · Investigational New Drugs · 2021 · 14 citations · Full text

Medicine, Oncology, Neoplasia +7

Differential responses to taxanes and PARP inhibitors in <i>ATM‐</i> versus <i>BRCA2</i>‐mutated metastatic castrate‐resistant prostate cancer

Christopher Su, Emily Nizialek, Jacob E. Berchuck et al. · The Prostate · 2022 · 13 citations · Full text

Medicine, Oncology, Pharmacology +13